Regeneron Pharmaceuticals (MIL:1REGN) Marketable Securities : €4,865 Mil (As of Mar. 2025)

View and export this data going back to 2023. Start your Free Trial

What is Regeneron Pharmaceuticals Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Regeneron Pharmaceuticals's Marketable Securities for the quarter that ended in Mar. 2025 was €4,865 Mil.

Regeneron Pharmaceuticals's annual Marketable Securities increased from Dec. 2022 (€4,377 Mil) to Dec. 2023 (€7,441 Mil) but then declined from Dec. 2023 (€7,441 Mil) to Dec. 2024 (€6,231 Mil).

Regeneron Pharmaceuticals Marketable Securities Historical Data

The historical data trend for Regeneron Pharmaceuticals's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Marketable Securities Chart

Regeneron Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Marketable Securities

Get a 7-Day Free Trial

1,145.29

2,486.05

4,376.76

7,441.27

6,230.71

Regeneron Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Marketable Securities	Get a 7-Day Free Trial															7,284.10	7,328.23	7,014.02	6,230.71	4,864.76

Regeneron Pharmaceuticals Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Regeneron Pharmaceuticals (MIL:1REGN) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Regeneron Pharmaceuticals Marketable Securities Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Regeneron Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (MIL:1REGN) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

REGN:USA REGN:Mexico 0R2M:UK RGO:Germany REGN34:Brazil REGN:Austria

Address

777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707

Website

https://www.regeneron.com

Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Regeneron Pharmaceuticals Headlines

No Headlines